Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M.

Clin Pharmacol Ther. 2006 Jan;79(1):103-13.

PMID:
16413245
2.
3.

Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Desta Z, Zhao X, Shin JG, Flockhart DA.

Clin Pharmacokinet. 2002;41(12):913-58. Review.

PMID:
12222994
4.

CYP2C19 polymorphism and proton pump inhibitors.

Klotz U, Schwab M, Treiber G.

Basic Clin Pharmacol Toxicol. 2004 Jul;95(1):2-8. Review.

5.
6.
7.

Pharmacogenomics of proton pump inhibitors.

Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T.

Pharmacogenomics. 2004 Mar;5(2):181-202. Review.

PMID:
15016609
8.

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.

Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T.

Drug Metab Pharmacokinet. 2005 Jun;20(3):153-67. Review.

9.

Pharmacokinetics of proton pump inhibitors in children.

Litalien C, Théorêt Y, Faure C.

Clin Pharmacokinet. 2005;44(5):441-66. Review.

PMID:
15871633
10.

Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.

Furuta T, Takashima M, Shirai N, Xiao F, Hanai H, Ohashi K, Ishizaki T.

Clin Pharmacol Ther. 2000 Jun;67(6):684-9. Review.

PMID:
10872651
11.

[Cytochrome P450 2C19 genotype -based second line therapy with amoxicillin and lansoprazole after failure of initial helicobacter pylori eradication therapy].

Asano M, Taniwaki H, Tsuji D, Sato Y, Shimizu T.

Nihon Rinsho. 2005 Dec;63 Suppl 12:450-3. Review. Japanese. No abstract available.

PMID:
16416832
12.

CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase.

Zhou HH.

Clin Chim Acta. 2001 Nov;313(1-2):203-8. Review.

PMID:
11694260
13.

[Recent topics on important drugs for H. pylori eradication: Omeprazole].

Kataoka H, Jho T, Itoh M.

Nihon Rinsho. 2005 Nov;63 Suppl 11:333-7. Review. Japanese. No abstract available.

PMID:
16363556
14.

Pharmacogenetics of the proton pump inhibitors: a systematic review.

Chong E, Ensom MH.

Pharmacotherapy. 2003 Apr;23(4):460-71. Review.

PMID:
12680476
15.

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.

Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmöller J.

Mol Psychiatry. 2004 May;9(5):442-73. Review.

PMID:
15037866
17.
18.

[The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases].

Alonso-Navarro H, Jiménez-Jiménez FJ, García-Agúndez JA.

Med Clin (Barc). 2006 May 13;126(18):697-706. Review. Spanish.

PMID:
16759580
19.

Genetics of response to proton pump inhibitor therapy: clinical implications.

Dickson EJ, Stuart RC.

Am J Pharmacogenomics. 2003;3(5):303-15. Review.

PMID:
14575519
20.

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.

Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J.

Br J Clin Pharmacol. 2010 Mar;69(3):222-30. doi: 10.1111/j.1365-2125.2009.03578.x. Review.

Supplemental Content

Support Center